ArticleThe Canadian journal of urology2026
Understanding the utilization of genetic counseling and testing among patients with prostate cancer.
Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesProstate cancer (PCa) progression is influenced by a myriad of germline and/or somatic variants estimated to occur in 4.6%-11.8% of patients. Identified pathogenic variants may carry implications for treatment selection and prognosis. Despite the importance of genetic testing, referrals to counselling remain underutilized by urologists. This study aimed to understand referral patterns, testing uptake, and genetic results among men with PCa at a single large academic center.
methodsRecords from 2010 to 2022 at Emory University were reviewed to identify men undergoing prostate biopsy and subsequent genetic counselling (CPT 96040). Referrals were confirmed as PCa-related and assessed against contemporaneous National Comprehensive Cancer Network (NCCN) criteria. Referral origin, genetic testing completion rates, and results were collected. Descriptive statistics summarized relevant results.
resultsOf the 6995 prostate biopsies performed over the study period, only 70 of these patients saw a genetic counselor, of whom 49/70 (70%) were referred for PCa between 2010 and 2022, all meeting contemporary criteria for testing. Indications included high-risk disease (36.7%), metastatic disease at presentation (20.4%), and family history/ancestry (42.9%). Referrals increased from 0 prior to 2015 to 12 in 2022. Most originated from medical oncology (44.9%) or self-referral (12.2%), with urologists accounting for only 6.1%. Of those referred, 45 (91.8%) underwent genetic testing; 62.2% had negative results, 24.4% variants of unknown significance (VUS), and 4.4% tested positive for PCa-related pathogenic variants.
conclusionsAlthough referrals increased over time with guideline evolution, urologists accounted for a minority of referrals. While most results were negative or uncertain, pathogenic variants likely carried therapeutic significance. Addressing barriers to referral and improving integration of genetic services into urologic practice may help improve PCa care.
Indexed as
Identifiers
42415575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.